Freenome starts 20,000-subject study of lung cancer blood test

Freenome has started a clinical trial to evaluate the ability of its blood test to detect lung cancer early in an at-risk population.
The trial will enroll 20,000 current and former smokers aged 50 years and older who are eligible for screening with a low-dose CT scan. In 2022, 4.5% of eligible people were screened for lung cancer.